logo

Sorry, but the browser version you are currently using is not supported by this website. We recommend that you update or download a more recent version.

Theraxium
Oncology

The digital therapeutic
for people with cancer
and their care teams

GO TO THE WEBSITE

We innovate

healthcare
solutions

by embedding connectivity in therapeutics
and medical intelligence in software

With excellence and innovation at heart,

Voluntis designs
state-of-the-art solutions

for chronic and rare diseases to empower patients by embedding intelligence in mobile phones and to simplify care provision by powering health data management.

We innovate

healthcare solutions

by embedding connectivity in therapeutics
and medical intelligence in software

With excellence and innovation at heart,

Voluntis designs
state-of-the-art solutions

for chronic and rare diseases to empower patients by embedding intelligence in mobile phones and to simplify care provision by powering health data management.

WHO WE ARE


Voluntis was founded in 2001 by three entrepreneurs who believed that innovative medical solutions built with advanced information technologies would improve medical real-life outcomes and thus increase healthcare system efficiency. This would transform patient lives, enhance medical practices and quality of care.

Every day, Voluntis teams seek to invent secure, collaborative and patient-centric digital health solutions with a unique combination of web and mobile development excellence, medical and regulatory expertise and certified quality-oriented processes. With more than 600,000 patients managed and more than 50 programs deployed, our track record speaks for itself.

  • 600,000
    patients managed
  • 50
    programs deployed

At Voluntis, we are all guided by clear and simple values:

  • Patient focus: we are committed to changing the daily lives of patients by addressing their unmet needs and by empowering them to manage their chronic conditions.
  • Passion for innovation: we design next-generation solutions that combine digital and medical expertise to solve the daily problems of patients and caregivers.
  • Respect and integrity: everyday, we take care of the people we touch, our patients, customers, partners and employees.
  • Drive for excellence: in everything we do, we behave ethically and we strive to attain the highest level of quality. Always working to enhance our processes, we are certified ISO 9001 and ISO 13485 (regarding quality management systems). We are also compliant with ISO 14971 standards (risk management). Our design methodologies embed the harmonized IEC 62304 and IEC 62366 standards (for medical device software).
Alexandre CAPET

Alexandre CAPET

DEPUTY CEO, CHIEF STRATEGY & MARKETING OFFICER, DIABETES DIVISION COORDINATOR

Before joining Voluntis, Alexandre worked 15 years in the pharmaceutical industry. At Sanofi, he notably headed the Group's strategic planning and M&A for France, where he strongly contributed to building the Diabeo partnership with Sanofi, CERITD and Voluntis. Alexandre is a graduate of HEC Paris and Sciences Po Paris. He holds a master's degree in health economics from Paris-Dauphine University.

Pierre LEURENT

Pierre LEURENT

Chief Executive Officer and founder

Pierre has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco. In addition, Pierre is the Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Pierre is a graduate of the Ecole Centrale Paris engineering school.

Romain MARMOT

Romain MARMOT

DEPUTY CEO, CHIEF OPERATING OFFICER - US, ONCOLOGY DIVISION COORDINATOR, CO-FOUNDER

Romain is Chief Operations Officer of Voluntis and heads the company’s North American operations in Cambridge, MA. He has more than 15 years of experience in digital health and software medical devices. He holds an MSc from École Centrale Paris in applied mathematics.

Matthieu Plessis

Matthieu PLESSIS

Chief Financial Officer

Matthieu has 25 years of experience in various finance positions in the pharmaceutical, telecom and IT industries. Prior to joining Voluntis, he was CFO of eFront, a global financial software vendor. In this position, he successfully supported the group’s rapid growth as well as it’s finance and M&A operations. Previously, he worked for Glaxo and SFR-Cegetel. He is a graduate of ESSCA management school.

Dr Geneviève D'ORSAY

Geneviève D'ORSAY

MD, Chief Medical Officer

Geneviève has more than 20 years of experience in the life sciences industry. Before joining Voluntis, she was Medical Affairs Director for Johnson & Johnson Medical Devices & Diagnostics for France & BeNeLux. Prior to this position, she worked for Altana Pharma, Chiesi and Bioprojet. She holds a doctorate in medicine and a degree in pharmacology and clinical research from University of Paris VI as well as a degree in pharmacovigilance from University Descartes, Paris.

Matthieu Plessis

Matthieu PLESSIS

Chief Financial Officer

Matthieu has 25 years of experience in various finance positions in the pharmaceutical, telecom and IT industries. Prior to joining Voluntis, he was CFO of eFront, a global financial software vendor. In this position he successfully conducted an IPO in Europe, as well as the trade public to private sale of the company. Previously, he worked for Glaxo, SFR-Cegetel and Cegetel Enterprises. He is a graduate of ESSCA management school.

Etienne VIAL

Etienne VIAL

Vice President Innovation and Co-Founder

Etienne manages the innovation activities at Voluntis. Etienne has more than 12 years of experience in building frameworks, deploying m-health solutions and developing algorithms, analytic suites and interoperable software. He is a graduate of the École Centrale Paris engineering school.

Patrick Alff

Patrick ALFF

Vice President Engineering and Services

Patrick heads our Engineering and Services department where he leverages his solid international management experience, with a heavy emphasis on the development of enterprise software and cloud services. Former Head of Technology Strategy at British Telecom, Director of Technology at Infonet in California, VP of R&D and Innovation at OpenTrust and IT transition manager with several other companies, Patrick is keen to promote change, innovation and customer satisfaction. He enjoys combining his entrepreneurial spirit with his passion for technology and management.

Raffi KRIKORIAN

Raffi KRIKORIAN

Vice President Quality & Regulatory Affairs

Raffi has 15+ years of experience in the medical device industry. Prior to joining Voluntis, Raffi was Manager at Hutchinson Santé, healthcare subsidiary of Hutchinson Group, where he headed R&D, manufacturing and regulatory affairs in an international environment. Raffi is a graduate of the Ecole Nationale Superieure de Chimie de Mulhouse and holds a PhD in polymer science. He also holds an MBA from ESCP Europe business school.

Damien MCKEON

Damien MCKEON

Vice-President Real-World Evidence

Damien is charged with extending Voluntis' real-world evidence capabilities, notably in the fields of outcomes measurement and data valuation. He trained in the UK as a pharmacist and computer scientist. He has over 15 years of experience in the pharmaceutical industry and in frontline clinical healthcare (at Portsmouth Hospitals NHS Trust and multiple pharmacies). He notably worked at AXA, where he helped build an operational framework to handle outsourced medical information services for pharmaceutical partners. In 2005 he led the preparation for the first ever UK Medicines and Healthcare Products Regulatory Agency inspection of this type of provider. He joined Voluntis in Paris in 2008 to take the helm of its quality division, obtaining QMS certification for ISO:13485 in 2010 and VITM/Diabeo’s CE Mark in 2013.

Aurore Beaume

Aurore BEAUME

Head of Business Development Europe

Aurore has over 10 years of experience in innovation and healthcare, in particular in developing strategy, business models and partnerships. Before joining Voluntis, she managed the innovation consulting practices for several firms such as Altran (Arendi Consulting), Erdyn and Sogeti High Tech. She specialized in life sciences, biotechnology, healthcare and digital. She created innovation strategies and business models for start-ups as well as large groups such as Phillips, bioMérieux and Pierre Fabre. She graduated from Ecole Polytechnique and Chimie ParisTech (National Chemical Engineering Institute in Paris) and also holds a PhD in pharmaceutical organic chemistry from UPMC (formerly Pierre and Marie Curie University, part of the Sorbonne University).

  • Pierre LEURENT

    Chief Executive Officer and Founder

    Pierre
    LEURENT

  • Romain MARMOT

    Deputy CEO
    Chief Operating Officer - US

    Romain
    MARMOT

  • Alexandre CAPET

    Deputy CEO
    Chief Strategy & Marketing Officer

    Alexandre
    CAPET

  • Etienne VIAL

    Vice President Innovation and
    Co-Founder

    Etienne
    VIAL

  • Dr Geneviève D'ORSAY

    Chief Medical
    Officer

    Geneviève
    D'ORSAY, MD

  • Aurore Beaume

    Head of Business Development Europe

    Aurore
    Beaume

  • Matthieu Plessis

    Chief Financial
    Officer

    Matthieu
    PLESSIS

  • Patrick Alff

    Chief Technology
    Officer

    Patrick
    ALFF

  • Raffi KRIKORIAN

    Vice President Quality & Regulatory Affairs

    Raffi
    KRIKORIAN

  • Damien MCKEON

    Vice-President Real-World Evidence

    Damien
    MCKEON

Eric Elliott

Chairman of the Board of Directors

In his most recent role as Prime Therapeutics' President and Chief Executive Officer, Eric Elliott was responsible for all operating and strategic aspects of the full service pharmacy benefit management company. With approximately $17 billion in annualized drug spend under management, Prime Therapeutics is the fourth largest pharmacy benefit manager in the United States, servicing 23 health plans, other smaller pharmacy benefit managers (PBMs), and employer direct customers. Critical to the success of Prime Therapeutics, Eric led the partnership with Blue Cross and Blue Shield Plans to ensure members receive the highest quality of care while managing appropriate pharmaceutical costs and trends. Under Elliott's leadership, Prime was recognized locally and nationally by prominent publications and organizations for its employee engagement, healthy workplace, highest quality and care of service for members, and business growth. With experience running three integrated PBMs, Eric is skilled in leading and growing businesses to include line and segment expansions. He previously served as president of Cigna's Pharmacy Management and Voluntary businesses and has held senior executive level positions at Aetna, PCS HealthSystems and Rite Aid Corporation. Elliott received his bachelor's degree in management and finance, and a Master of Business Administration from Temple University in Philadelphia. He has served for many years on the board of directors at Prime, The Main Street America Group, the Pharmaceutical Care Management Association and the Twin Cities American Heart Association. Elliott also serves on The Wall Street Journal CEO Council.

Pierre LEURENT

Director and Chief Executive Officer

Pierre has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco. In addition, Pierre is the Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Pierre is a graduate of the Ecole Centrale Paris engineering school.

Jan Berger

Director

Dr. Berger is a tri-sector healthcare executive with proven results in private, public and government services over the last 30 years. In 2009, Dr. Berger founded Health Intelligence Partners as a health care consultancy where she has advised in 14 countries with both health organizations and national ministries of health. Prior to that, she served as Senior Vice President, Chief Clinical Officer and Innovation Officer for CVS Health/Caremark. She currently sits on the boards of Cambia Health Solutions, a multi-state Blue Cross Blue Shield plan; GNS Healthcare, a healthcare data analytics company; Tabula Rasa, a medication safety and management company; and Accent Care, a home health and palliative care organization. Dr. Berger is an assistant professor at Northwestern University School of Medicine and School of Communication in Chicago, Illinois. She is a renowned expert in consumer engagement and medication adherence and has authored four books and numerous publications on these topics. She holds both a Doctor of Medicine degree and a Master’s in Jurisprudence from Loyola University (Chicago, Illinois).

Jean Bertin

Director

Jean Bertin is an Investment Principal at Bpifrance Large Venture, a €600m vehicle investing in high-growth innovative companies with significant capital requirements (>€20m) in the Healthcare and Tech spaces. Since he joined Large Venture in 2013, he focuses and accompanies portfolio companies in the digital and medtech sectors and has invested in Voluntis, Scality, Biom’up, Pixium Vision and Isorg. He has been active in the startup environment for the past 7 years, first as an intern at Naxicap Partners then as a project manager for a solar PV developer and business development consultant for a desalination company. He then joined the Caisse des Dépôts group as an investor in the cleantech sector at CDC Climat. Jean Bertin holds an MBA from ESSEC Business School (Paris/Singapore).

Nicolas Cartier

Director

Nicolas Cartier is Corporate Vice President, Industrial Microbiology Unit of bioMérieux and member of bioMérieux’s Executive Committee. Before joining bioMérieux, Nicolas was General Manager of Sanofi France from 2009 to 2013. Prior to that, he held various internal positions within Sanofi, in particular in Thailand, where he was in charge of commercial development for the Southeast Asia region within the Animal Health Division; in Shanghai, where he headed up Sanofi China’s Pharmaceutical Division; and in Mexico City, where he was General Manager of Sanofi Mexico. In addition, Nicolas was Chief of Staff of the Chairman and CEO of Sanofi. Nicolas is a graduate of École Polytechnique, École des Ponts and Institut d’Études Politiques de Paris.

Roberta Herman

Director

Dr. Herman currently works as the Executive Director of the Group Insurance Commission of Massachusetts. She is charged with modernizing the state agency through new solutions to better insure and care for state employees and retirees. Prior to her current role, she was co-leader for payer/provider value transformation in the healthcare strategy practice at Navigant Consulting. Until 2013, she served as the Chief Operating Officer and Chief Medical Officer of Harvard Pilgrim Health Care, a Massachusetts based health insurance plan serving 1.2 million commercial and Medicare members across three states. She currently serves on the Board of the Joslin Diabetes Center. Dr. Herman has taught at Harvard Medical School and often guest lectures at the Harvard School of Public Health. She graduated from McGill University Medical School (Montreal, Canada).

Viviane Monges

Director

Viviane Monges has 30 years of experience as a Senior Executive in the finance function. She has had a successful career in international companies, holding positions in Europe, Asia and the United States, mostly in the healthcare sector. After five years at Agence France Presse in Paris and then Hong Kong, she joined the pharmaceutical industry with Wyeth, first in the French subsidiary as director of management control, then at the group's head office in Philadelphia, as Chief Financial Officer of the Europe Region, then of the Pharma Business Unit (USD 6 billion). She took an active role in many projects to transform the company, organisationally, strategically and in mergers & acquisitions and to establish the Sarbanes-Oxley rules on internal control. In 2006, Viviane joined the OTC Division at Novartis as Chief Financial Officer, Europe. She took part in many key projects, including a reorganisation of the Europe Region as well as the establishment of shared service centres. Next, she served as Global CFO of the OTC Division based in the United States (USD 3.5 billion) during the Prevacid launch. In 2010, Viviane was appointed CFO of Galderma, a Swiss pharmaceutical group specialised in dermatology (USD 2.5 billion). This group, a joint venture of Nestlé and L'Oréal, is an industry leader in Rx, OTC, and Aesthetics. In 2014, following Nestlé's acquisition of all of Galderama's shares, the latter became Nestlé Skin Health. In 2015, Viviane joined Nestlé as CFO of the Business Excellence Department, which groups together the worldwide support functions (finance, HR, IT, procurement, digital and property). For three years, Viviane has been responsible for a major programme to transform the group. In 2018, Viviane decided to focus on directorship. She is a member of the board of directors of UCB and Novo Holdings. Viviane is a graduate of ESCP, a French national, and a resident of Lausanne.

Franck Noiret

Director

Franck Noiret is Managing Director of Innovation Capital at LBO France, a leading private equity firm with over 3 billion euros under management. He joined Innovation Capital in 2005 as General Partner, and LBO France in 2016 when the firms joined forces. He is currently investing in Digital Health companies in Europe through the Services Innovants Santé et Autonomie (SISA) fund. With over 20 years of investment experience in Technology and Healthcare, Franck Noiret is currently board member of Voluntis, Entrepreneurs & Investisseurs Technologies, Kayentis, Omni Orthopaedics (US), Zesty (UK) and observer of Ekinops (EKI / Euronext). Prior to joining Innovation Capital, Franck Noiret was Director at Apax Partners in Paris where he was responsible for investments in Technology and Telecoms ranging from venture capital to growth LBO. From 1995 to 2000, Franck Noiret was Principal Banker at the European Bank for Reconstruction and Development (EBRD) where he was responsible for private and public sector investment projects in Central and Eastern Europe. De 1989 à 1993, Franck Noiret was a banker in the City of London for Société Générale after starting his career as an auditor at Arthur Andersen in Paris. Franck Noiret has a MBA from the Wharton School (US) and a Master in Corporate Finance from Paris-Dauphine University. He graduated with the highest distinction from Sciences Po Paris.

Timothy Jackson

Observer

Timothy is a Manager of Finance at Qualcomm Ventures focusing on early stage investments. He is also responsible for market investment analysis, due-diligence, and deal execution for Qualcomm Ventures. Prior to joining Qualcomm Ventures, Timothy worked in Qualcomm’s corporate finance division as an analyst in Financial Planning and Analysis as well as the Legal and Patent organization. Timothy holds a BS in finance from Boston College, a JD from the UCLA School of Law, and an MBA from UC San Diego’s Rady School of Management.

Alain Parthoens

Observer

Alain Parthoens is co-founder and managing partner of Vesalius Biocapital funds I & II. He launched his first pan-European life science venture capital fund end of 2007 (VBC I, €76M raised) invested in 11 life science companies. In 2011, Vesalius raised its second fund (VBC II), reaching €78M which has permitted investments in six companies for the time being. Alain Parthoens has 12 years of experience as a venture capitalist with Vesalius Biocapital as well as ING Bank, where he was the life sciences investment director for southwestern Europe. Since 2001, he has invested in almost 30 early stage life science companies, most of the time in a leading role. As board member, he has actively participated in the development of several of them. Additionally, Alain Parthoens has many years of international experience working with food and life science companies, such as Nestlé, Kemira and Monsanto, and as an R&D consultant for pharmaceutical companies with PriceWaterhouseCoopers in London. He was the chairman of the Belgian Venture and Private Equity Association. He is now a member of EVCA VC Council. Alain holds an MSc in agronomy and specialty biochemistry from the Université Catholique de Louvain, an MSc in finance and computer sciences from Université Libre de Bruxelles and a management degree from the Solvay Business School.

OUR VISION

We firmly believe that the unprecedented advancement of information
technologies will contribute to solving certain healthcare system issues,
notably related to chronic disease expansion.



At Voluntis, we believe these remarkable changes are the pivotal factors that are already transforming healthcare systems. We are poised and ready to catapult the best from advanced technologies to improving healthcare.

Committed to this vision, Voluntis designs digital therapeutics that transform healthcare by:

  • designing integrated care services
  • aligning the interests of patients, providers and payers
  • driving costs down while improving quality
  • establishing a collaborative relationship between patients and their doctors

OUR OFFER


DIGITAL THERAPEUTICS

At Voluntis, we develop state-of-the-art digital therapeutics to accompany
and enhance a specific medication or medical device.

We design our digital therapeutics in a user-friendly manner
to augment the real-life value of therapeutics by:

For example, we design clinical algorithms that support decision-making, such as medication dosage.

For example, we securely connect patients with caregivers to activate remote operations, such as monitoring, treatment adjustment or coaching.

For example, we promote data sharing between doctors and patients to foster engagement and enable effective task delegation among healthcare professionals so as to optimize time.


As an accompaniment to existing medication or medical devices, digital therapeutic apps aim to monitor side effects, guide symptom management, promote protocol adherence, recommend dosage or connect patients with their healthcare teams.

According to prevailing regulations, our digital therapeutics could be classified as a software medical device. To strictly comply with regulations, Voluntis has developed extensive regulatory expertise and implemented high quality standards.

As such, digital therapeutics have the potential to empower patients, prevent complications and, ultimately, augment the real-life value of a medication.

We conduct clinical studies to demonstrate the value and medical benefits of our digital therapeutics. In the diabetes m-health field, our digital therapeutic solution is the most extensively studied on the market.

Voluntis develops proprietary digital therapeutics but also provides partners with development and regulatory capabilities to elaborate their own.

OUR EXPERTISE


Theraxium is a comprehensive and highly flexible platform that transforms health data into medical intelligence for better care.

Voluntis develops proprietary digital therapeutics but also provides partners with development and regulatory capabilities to elaborate their own digital solution based upon its Theraxium core system architecture.


Operated on the Cloud, Theraxium is a modular
web-based and mobile platform that can:

Management of device interoperability and seamless integration.

Security management and compliance with privacy rules.

Through configurable roles and workflows to coordinate the activities of care providers.

Analysis and retrieval of relevant information, using an analytics suite that incorporates clinical algorithms, automated notification or dashboards to support medical decisions.

Automated effective recall of software medical devices.



The cornerstone

A modular platform, Theraxium enables healthcare organizations to monitor patients remotely, support patient assistance programs (therapeutic education for instance), track adverse events and prompt compliance.

Theraxium is also the cornerstone of our digital therapeutics. Tailored to design mobile applications, Theraxium is the underlying platform of our solutions dedicated to diabetes, respiratory diseases, cancer, hemophilia and anticoagulation.


Proven reliability

A highly flexible framework, Theraxium has proven its reliability through its implementation in 50+ programs covering more than 20 therapeutic fields. Six top 10 pharmaceutical leaders have deployed Theraxium to support patient-centric initiatives. It has provided support and monitoring to over 610,000 patients in 12 countries.

With over 50 e-health and m-health projects deployed, the Voluntis team has developed a unique expertise in developing software medical devices.

We combine flexibility with regulatory compliance; our quality certified project methodology aims to deliver state-of-the-art products and solutions by following the Agile Manifesto, relying on an interactive approach that encourages:

  • interaction
  • task parallelization
  • responsiveness
  • and customer collaboration

Beyond being your single point of contact, your Voluntis project manager ensures that your project fully meets your expectations, timeline and budget throughout design, development, validation and delivery phases.

In addition to traditional software management, your Voluntis project manager addresses all topics specific to medical device manufacturing (such as human factors, product/patient risk management and clinical evaluations) with our experts.

Focused on patient safety and driven by excellence,
Voluntis’ teams put quality at the heart of what they do.

Since 2008, our Quality Assurance department has ensured compliance with regulations and standards, trained employees in our quality processes and managed our product regulatory clearance and registration.


OUR DIGITAL THERAPEUTICS


Our diabetes solutions are designed to support type 1 and type 2 diabetes patients throughout the insulin therapy pathway. Our digital therapeutics in diabetes are prescription medical devices.

Insulia®

Insulia® provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes while enabling the health care team to remotely monitor progress. A healthcare practitioner prescribes Insulia using their dedicated web portal and sets up the treatment plan rules that will adjust basal insulin dosing based on the person’s specific needs. The user then receives an activation code to get started with their personalized app. Once downloaded, the app uses blood glucose readings and any hypo symptoms to recommend doses in real-time. These are constantly updated using clinical algorithms built into the application. Data is automatically shared with the health care team, who can remotely monitor the patient’s progress toward their goal thanks to tailored notifications. This enables providers to deliver tailored telemedicine services, a practice increasingly supported by payers worldwide.

To learn more, visit insulia.com

Diabeo®

Diabeo® is a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen. It provides therapeutic and decision-making support for effective diabetes management to help adult patients dose their basal and bolus insulin, facilitate interactions between patients and their healthcare professionals, support remote management and the implementation of telemedicine services. Diabeo® suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. Diabeo® was conceived as part of an extensive clinical program including 3 clinical studies conducted in partnership with Sanofi and the CERITD over the past 10 years.

Diabeo® is a regulated healthcare product that was granted a CE Mark in 2013. Diabeo® is not approved for use in the United States.

Diabeo® is a registered trademark of Sanofi.
Insulia® is a registered trademark of Voluntis.

COAGULATION

In anticoagulation treatments, compliance is crucial: the INR (International Normalized Ratio) must be regularly measured to ensure the appropriate dosage of the vitamin K antagonist treatment.

In collaboration with Roche Diagnostics, Voluntis has developed a digital therapeutic to enhance the CoaguChek INR self-testing device.

This solution, named CoaguChek Link, centralizes the INR data measured by patients, connects patients with the independent diagnostic testing facility and enables effective telemonitoring by healthcare professionals.

Thus, CoaguChek Link simplifies care delivery, ensures compliance and enables doctors and patients to stay connected and work together on managing the anticoagulant treatment.

HEMOPHILIA

In hemophilia, we work to help patients manage their condition. Our innovative solution aims to simplify the remote monitoring of bleeding events as well as inventory medication management.